Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: appraisal consultation (7th August 2008)
The Department of Health has asked the National Institute for Health and Clinical Excellence (NICE or the Institute) to conduct a multiple technology appraisal of bevacizumab, sorafenib, sunitinib and temsirolimus and provide guidance on their use to the NHS in England and Wales. The Appraisal Committee has had its first meeting to consider both the evidence submitted and the views put forward by non-manufacturer consultees and commentators, and by the clinical specialist and patient expert representatives nominated for this appraisal by non-manufacturer consultees and commentators. The Committee has developed preliminary recommendations on the use of bevacizumab, sorafenib, sunitinib and temsirolimus. Closing date for comments is 29th August 2008.
Consultation
Evaluation Report
Rheumatoid arthritis in adults: consultation on the draft guideline (8th August 2008)
A clinical practice guideline on Rheumatoid Arthritis is being developed for use in the NHS in England, Wales and Northern Ireland. Registered stakeholders for this guideline are invited to comment on the provisional recommendations. Although individuals and organisations not registered as stakeholders are able to comment, NICE recommend that you contact the registered stakeholder organisation that most closely represents your interests and pass your comments to them. Closing date for comments is 3rd October 2008.
Full Guideline
NICE Guideline
Evidence tables
Algorithms
Health Economic evidence tables
Antisocial personality disorders (ASPD): Consultation on the draft guideline (8th August 2008)
A clinical practice guideline on Antisocial personality disorders is being developed for use in the NHS in England, Wales and Northern Ireland. Registered stakeholders for this guideline are invited to comment on the provisional recommendations. .Although individuals and organisations not registered as stakeholders are able to comment, NICE recommend that you contact the registered stakeholder organisation that most closely represents your interests and pass your comments to them. Closing date for comments is 2nd October 2008.
Full Guideline
NICE Guideline
Comments proforma
Appendices
Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: final appraisal determination (8th August 2008)
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir and submitted it to the Institute. The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales. Please note that the appeal period for this appraisal will close at 5pm on 22 August 2008.
Final appraisal determination
Response to consultee, commentator and public comments
Consultee and commentator comments
The Department of Health has asked the National Institute for Health and Clinical Excellence (NICE or the Institute) to conduct a multiple technology appraisal of bevacizumab, sorafenib, sunitinib and temsirolimus and provide guidance on their use to the NHS in England and Wales. The Appraisal Committee has had its first meeting to consider both the evidence submitted and the views put forward by non-manufacturer consultees and commentators, and by the clinical specialist and patient expert representatives nominated for this appraisal by non-manufacturer consultees and commentators. The Committee has developed preliminary recommendations on the use of bevacizumab, sorafenib, sunitinib and temsirolimus. Closing date for comments is 29th August 2008.
Consultation
Evaluation Report
Rheumatoid arthritis in adults: consultation on the draft guideline (8th August 2008)
A clinical practice guideline on Rheumatoid Arthritis is being developed for use in the NHS in England, Wales and Northern Ireland. Registered stakeholders for this guideline are invited to comment on the provisional recommendations. Although individuals and organisations not registered as stakeholders are able to comment, NICE recommend that you contact the registered stakeholder organisation that most closely represents your interests and pass your comments to them. Closing date for comments is 3rd October 2008.
Full Guideline
NICE Guideline
Evidence tables
Algorithms
Health Economic evidence tables
Antisocial personality disorders (ASPD): Consultation on the draft guideline (8th August 2008)
A clinical practice guideline on Antisocial personality disorders is being developed for use in the NHS in England, Wales and Northern Ireland. Registered stakeholders for this guideline are invited to comment on the provisional recommendations. .Although individuals and organisations not registered as stakeholders are able to comment, NICE recommend that you contact the registered stakeholder organisation that most closely represents your interests and pass your comments to them. Closing date for comments is 2nd October 2008.
Full Guideline
NICE Guideline
Comments proforma
Appendices
Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir: final appraisal determination (8th August 2008)
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir and submitted it to the Institute. The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales. Please note that the appeal period for this appraisal will close at 5pm on 22 August 2008.
Final appraisal determination
Response to consultee, commentator and public comments
Consultee and commentator comments
Latest Implementation Tools (13th August 2008)
Stroke
Costing Template
Diabetes - insulin pump therapy
Costing Template
Audit Support
Direct skeletal fixation of prosthethes using intraosseous transcutaneous implants
Audit support
Induction of labour
Costing Statement
Preventing the uptake of smoking by children and young people
Costing Template
Coronary artery disease - drug-eluting stents
Costing Template
Audit Support
Respiratory tract infections
Costing Template
No comments:
Post a Comment